Stockhub

DBV Technologies S.A.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

19 August 2022

12 August 2022

5 August 2022

  • curprev 23:2023:20, 5 August 2022 >Paris 1,115 bytes +1,115 Created page with "DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of..."
Retrieved from "https://stockhub.co/research/DBV_Technologies_S.A."